TBC1D2

Across TCGA pan-cancer cohorts, TBC1D2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TBC1D2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TBC1D2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TBC1D2 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, PDAC, and COAD are the cancer types where TBC1D2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBC1D2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.962	<.001	12	view →
PDAC	Female	II,III,IV	+0.919	<.001	10	view →
COAD	Male	II,III,IV	+0.435	<.001	9	view →
LUAD	Male	All	−0.317	<.001	8	view →
HNSC	All	II,III,IV	+0.281	<.001	6	view →
LSCC	All	All	−0.169	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TBC1D2–CCRCC

Open the CCRCC breakdown →